Darbepoetin alfa

Drug Profile

Darbepoetin alfa

Alternative Names: Aranesp; Darbepoetin-α; KRN-321; Nesp; Nespo; Novel erythropoiesis stimulating protein

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Kirin-Amgen; Kyowa Hakko Kirin
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • Phase III Breast cancer

Most Recent Events

  • 07 Jun 2017 Amgen terminates phase III trial in Anaemia (Chemotherapy-induced) in Ukraine, Taiwan, Spain, Slovenia, South Africa, Serbia, Russia, Romania, Puerto Rico, Poland, Philippines, Mexico, Malaysia, South Korea, Luxembourg, Italy, Ireland, India, Croatia, China, Chile, Bulgaria, Brazil, Austria, Argentina (SC) (NCT0858364)
  • 20 Mar 2017 Amgen completes a phase III trial for Anaemia (in patients with myelodysplastic syndromes) in Belgium (NCT02175277)
  • 03 Dec 2016 Efficacy data from the phase III Arcade trial in Anaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top